Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc. (INM)
Filing Type: Form 8-K (Current Report)
Date of Report: December 12, 2025
Reporting Period: Event-based report regarding a specific legislative development.
Business Context: The Company is an emerging growth company incorporated in British Columbia, Canada, with principal executive offices in Vancouver. It operates a subsidiary, BayMedica Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory event rather than periodic financial performance.
Material Changes
Legislative Impact: On December 12, 2025, the Company issued a news release concerning the potential impact of H.R. 5371, the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026." This legislation was recently signed into law in the United States and affects BayMedica Inc., a subsidiary of InMed Pharmaceuticals Inc.
Guidance, Outlook, and Risks
- Forward-Looking Information: The attached news release (Exhibit 99.1) contains forward-looking statements regarding the impact of the new legislation.
- Risk Factors: The filing includes a cautionary note identifying important factors that could cause actual results to differ materially from the forward-looking information provided.
- Management Commentary: The report was authorized by Eric A. Adams, President & CEO.
Investor Verification Checklist
- Review the full text of the news release attached as Exhibit 99.1 to understand the specific operational or financial implications of H.R. 5371 on BayMedica Inc.
- Verify the status of the "Continuing Appropriations... Act, 2026" and its specific provisions affecting the Company's subsidiary.
- Monitor subsequent filings for updates on how the legislative change impacts the Company's cash flow or strategic outlook.